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Background and aims: Vascular disease (VD), as assessed by history of myocardial infarction or peripheral 
artery disease or aortic plaque, increases stroke risk in atrial fibrillation (AF), and is a component of risk 
assessment using the CHA2DS2-VASc score. We investigated if systemic atherosclerosis as detected by 
ultrasound carotid plaque (CP) could improve the predictive value of the CHA2DS2-VASc score. 
Methods: We analysed data from the ARAPACIS study, an observational study including 2,027 Italian patients 
with non-valvular AF, in whom CP was detected using Doppler Ultrasonography.  
Results: VD was reported in 351 (17.3%) patients while CP was detected in 16.6% patients. Adding CP to the 
VD definition leaded to higher VD prevalence (30.9%). 
During a median [IQR] follow-up time of 36 months, 56 (2.8%) stroke/TIA events were recorded. Survival 
analysis showed that conventional VD alone did not increase the risk of stroke (Log-Rank: 0.009, p=0.924), 
while addition of CP to conventional VD was significantly associated to an increased risk of stroke (LR: 5.730, 
p=0.017).  Cox regression analysis showed that VD+CP was independently associated with stroke (HR: 1.78, 
95% CI: 1.05-3.01, p=0.0318). Reclassification analysis showed that VD+CP allowed a significant risk 
reclassification when compared to VD alone in predicting stroke at 36 months (NRI: 0.192, 95% CI: 0.028-
0.323, p=0.032). 
Conclusions: In non-valvular AF patients the addition of ultrasound detection of carotid plaque to conventional 
VD significantly increases the predictive value of CHA2DS2-VASc score for stroke. 
 

















Atrial fibrillation (AF) is the most common sustained arrhythmia encountered in clinical practice, accounting for 
approximately one-third of all hospitalizations for a cardiac rhythm abnormality [1]. AF is associated with a 
fivefold increased risk for stroke, and is estimated to cause 15% of all strokes [2].  Based on evidence from 
many randomized clinical trials, AF patients are treated with oral anticoagulants such as warfarin or the non-
Vitamin K antagonist oral anticoagulants (NOACs) to reduce the risk of thromboembolic stroke [3].  
 
There is increasing evidence that AF is also associated with systemic signs of atherosclerosis, such as aortic 
plaque or low ankle/brachial index (ABI), which reflects the frequent coexistence of atherosclerotic risk factors 
such as hypertension, diabetes mellitus, dyslipidemia and metabolic syndrome [4, 5].  The coexistence of sub-
clinical systemic atherosclerosis suggests that clinical events complicating AF may be also attributable to 
athero-thrombosis in the carotid distribution [6]. Indeed, “vascular disease” (VD) increases stroke risk in non-
valvular AF (NVAF), and is a component of risk assessment using the CHA2DS2-VASc score [7]. The usual 
clinical definition of VD includes a history of MI or claudication with surgical intervention or the presence of 
aortic plaque. We argued that diagnosis of aortic plaque may be cumbersome in clinical practice as it is not a 
routine analysis and is invasive while carotid atherosclerosis as assessed by Doppler ultrasound is easier to 
perform, cheaper, not invasive and commonly used to define extra-cranial atherosclerosis in patients with risk 
factors.   
We therefore hypothesized that inclusion of carotid plaque in the CHA2DS2-VASc score would better define the 
prevalence of VD and possibly improve stroke risk prediction by CHA2DS2-VASc score in the AF population. 
We tested this hypothesis in the ARAPACIS study, an observational study including 2,027 Italian patients with 
NVAF, to investigate if documentation of carotid plaque, which was a predefined assessment of atherosclerotic 




We performed a post-hoc analysis from the “Atrial Fibrillation Registry for Ankle-brachial Index Prevalence 
Assessment: Collaborative Italian Study” (ARAPACIS) which was a prospective nationwide observational 
study, conducted by the Italian Society of Internal Medicine (SIMI), investigating the prevalence of 
















provided information on the prevalence of ABI and its relationship with classic risk factors of atherosclerosis in 
AF patients [4]. Furthermore, the study showed that, in NVAF, ABI was useful to discriminate patients 
experiencing MI but not stroke [8].  Details about study protocol and inclusion/exclusion criteria were elsewhere 
reported [9]. From 1
st
 October 2010 to 31
st
 October 2012 a total of 2,027 patients were enrolled and then 
followed up for three years up to 31
st
 October 2015. 
Study protocol was approved for the Coordinator Centre (Sapienza-University of Rome) with the number 
1902/17.06.2010. The study was subsequently registered at ClinicalTrials.gov (Unique identifier: 
NCT01161251). According to the list of enrolling centers reported in the Appendix, every institution’s Ethics 
Committee approved the study protocol. 
The study was conducted in accordance with the EU Guidance on Good Clinical Practice CPMP/ECH/135/95 
and the Declaration of Helsinki and its later amendments. 
As previously reported [9], all clinical variables of interest and all data about relevant pharmacological therapies 
were collected at the time of enrolment.  
Thromboembolic risk was categorized using CHA2DS2-VASc score, calculated by adding 1 point each for the 
presence of congestive heart failure (HF), hypertension, age from 65 to 74 years, diabetes mellitus, vascular 
disease (VD) and female sex, and adding 2 points for stroke or transient ischemic attack (TIA) and age 75 years 
or older [7]. Conventionally, previous MI or symptomatic PAD or aortic plaque defined VD.  
The presence of carotid plaque was declared in an electronic case report form. The investigator assessed the 
presence of an atherosclerotic plaque following the American Society of Echocardiography consensus statement 
[10] and carotid plaque (CP) was deﬁned as follows: 1) focal wall thickening that is at least 50% or greater than 
that of the surrounding vessel wall or 2) focal region with carotid intima media thickness greater than 1.5 mm 
that protrudes into the lumen that is distinct from the adjacent boundary. 
Assessment of cerebrovascular events (CVEs) 
An independent committee (P.F., S. M.L., P.P.E.) adjudicated adverse events. Occurrence of a CVE was 
defined for any ischemic stroke or transient ischemic attack (TIA) recorded during the follow-up observation. 
Ischemic stroke was determined on clinical manifestations and confirmed by radiological findings. 
Statistical Analysis 
Continuous variables were reported as mean±SD, or as median and interquartile range (IQR) as appropriate. 
Comparisons between groups of continuous variables were performed by t-test or Mann-Whitney U test. 
















test, when cell count was less than five. Kaplan-Meier curves were built for CVEs occurrence.  A log-rank test 
was performed to analyse differences in survival distributors between subgroups. Univariate and multivariate 
Cox models were used to assess clinically relevant variables (age, sex, any antithrombotic therapy, diabetes 
mellitus, statins, hypertension, heart failure, previous cardio- or cerebrovascular events, type of AF and 
enrolling center) and VD, as well as VD+CP, effects on the incident endpoint of CVEs.  A forward stepwise 
model selection procedure based on the AIC was used to select the best multivariate regression model. 
Improvement of VD+carotid plaque over VD alone was assessed by means of continuous Net Reclassification 
Index (NRI) and median improvement in risk scores (MIRS), which were computed as described by Pencina et 
al [11]. The NRI gives roughly the proportion of misclassified cases that are classified correctly with the new 
information, a NRI of 1 indicates perfect ability to correctly reclassify patients, and a negative NRI indicates 
that the new score is worse than its competitor. The NRI was evaluated at 12, 24 and 36 months. The Integrated 
Discrimination Improvement (IDI) is linked to the discrimination slope. A positive IDI indicates that a higher 
discrimination (difference in average predicted probability for events, compared with non-events) for the 
VD+carotid plaque over VD alone.  
Decision curve analysis (DCA) was computed as described in Vickers et al [12]. It shows the estimated number 
of patients that would opt for treatment if their risk of an event was above a threshold probability, for each 
threshold. DCA can be used to compare prediction models with respect to their net benefit.  
Time-dependent C-indexes were estimated by means of the Kaplan-Meier method of Heagerty et al. [13]. Their 
confidence intervals and p-values were estimated by means of non-parametric bootstrap. 
A two-sided p value <0.05 was considered as statistically significant.  All analyses were performed using SPSS 

















A detailed description of the overall cohort has been previously reported (9). Briefly, age (mean±SD) was 
73.3±10.0 years with 45.3% (918 patients) females. Of the NVAF types, 842 (41.5%) patients had paroxysmal 
AF, 284 (14.0%) were persistent AF and 901 (44.5%) had permanent AF. Hypertension was the most prevalent 
risk factor (82.5%). 
According to the conventional VD definition of the CHA2DS2-VASc score VD was defined as previous MI or 
symptomatic PAD or aortic plaque.  
VD was reported in 351 (17.3%) patients while CP was detected in 16.6% (n=336) patients. 
Among patients with VD, no significant difference in the occurrence of CVE was observed between patients 
with or without stroke (17.3 vs. 17.5%, respectively, p=0.963) (Figure 1).  Conversely, when the contemporary 
presence of CP was added to VD, a significant difference between patients with vs. without CVE was found 
(30.5% vs. 45.6%, respectively, p=0.015) (Figure 1).  
During a median [IQR] follow-up of 36 [22-36] months, 56 CVEs were reported, with an overall incidence of 
1.17 per 100 patient-years. Patients with CVEs were older (p<0.001) and with a positive history for previous 
stroke/TIA (p<0.001). They had higher CHA2DS2-VASc score (p<0.001) and more prevalent CHA2DS2-VASc 
score > 2 (p=0.036). Female patients were more represented in the group of CVEs patients, of borderline 
statistical significance (p=0.052) (Table 1).   
Conventional VD alone did not differentiate patients with and without CVEs during follow-up (p=0.963). CP 
was more prevalent in patients who experienced stoke/TIA during the follow-up (31.6% vs. 16.1%, p=0.002).  
Inclusion of CP in the VD definition led to a significant increase in VD prevalence [30.9%].  
 
Event-Free Survival Analysis 
Conventional VD did not discriminate AF patients who experienced CVEs during the follow-up (Log-Rank: 
0.009, p=0.924); conversely, CP presence discriminated patients who experienced stroke/TIA during the follow-
up (Log-Rank: 8.61, p=0.003).  Adding CP to conventional VD was associated with an enhanced risk of 
stroke/TIA [Log-Rank: 5.730, p=0.017, Figure 2].  
On Cox proportional hazards analysis (Table 2), adjusted for gender, AF type, heart failure, hypertension, 
statins, previous cardio-vascular event, enrolling center, any antithrombotic therapy and diabetes, VD+CP was 
















Reclassification Analysis, Decision Curve Analysis, and C-statistic 
Using NRI, adding CP to VD was significantly better than using conventional VD alone in predicting CVEs at 
24 months (p=0.0399) and 36 months (p=0.0332). Despite significant reclassification, no significant 
improvement was found according to IDI analysis (Table 3).  
DCA estimates the outcome in a decision-making process based on VD and VD+ CP. It shows that with VD 
alone a net benefit would not be obtained at all estimable thresholds, while for VD+ CP a rather steep decision 
curve is obtained, indicating that VD+ CP is useful in the decision-making process. VD+ CP had significantly 
greater C-statistic (Table 4) than conventional VD alone for CVEs at 24 and 36 months (p<0.001) 
Sensitivity Analysis 
To verify the role of VD+ CP in preventing the occurrence of CVEs, a sensitivity analysis in patients without 
previous history of stroke/TIA was performed. The analysis showed that in AF patients without a previous 





In the present study, inclusion of ultrasound detection of carotid plaque in the diagnosis of VD increased the 
predictive values of CHA2DS2-VASc score; this reinforces the concept that systemic atherosclerosis is another 
mechanism accounting for ischemic stroke in AF [6]. 
Previous study by ARA PACIS registry demonstrated AF is associated with atherosclerosis of extracranial 
carotid arteries, as assessed by carotid IMT, but its impact with cerebrovascular disease was not investigated 
[14]. The present analysis of the ARAPACIS registry supports and extends these finding by demonstrating that 
carotid plaque is detectable in approximately 17% of AF. Furthermore, during the follow-up, patients with CP 
were at higher risk of experiencing acute cerebral disease, thereby suggesting that atherosclerosis of carotid 
artery might also be implicated in cerebral ischemia. 
VD has been included in the CHA2DS2-VASc score to improve its ability to predict stroke in AF patients [7]. To 
further address the role of VD in predicting stroke the ARAPACIS registry investigated two markers of 
systemic atherosclerosis, namely ABI and CP, to assess their predictive values versus cerebral and coronary 
heart disease in AF population. While we found that ABI is able to predict coronary heart disease [8], the 















vascular disease.  Thus, CP had more frequently detected in AF experiencing CVEs compared to those without 
CP and independently predicted CVEs after adjusting for confounding variables. Analysis of CP greatly 
increased the prevalence of VD, which was 17% by conventional definition and 30% by adding CP to 
conventional VD definition. Then, by including CP in the VD definition, this also improved the predictive value 
of VD for predicting stroke/TIA compared to conventional VD definition, suggesting that ultrasound detection 
of carotid plaque may be useful to stratify patients at risk of stroke/TIA in the AF population. 
We provide further support to the inclusion of VD as a variable predicting ischemic cerebro-vascular disease in 
AF population and suggest that CP improves the performance of the CHA2DS2-VASc score. This finding 
supports and extends a previous study reporting that inclusion of carotid plaque in the CHA2DS2-VASc score 
improves its predictive value in an AF population not on treatment with warfarin [15]. Our finding reinforces 
also the concept that in AF population ischemic stroke is not only of thrombo-embolic but also of athero-
thrombotic origin. This suggestion has therapeutic implications as it implies that non-valvular AF could benefit 
not only from oral anticoagulants but also possibly from anti-atherosclerotic drugs [16]. Thus, further study is 
needed to see if adding anti-atherosclerotic drugs such statins, which also possess anti-thrombotic properties 
[16], in addition to oral anticoagulants may be of benefit in further reducing the risk of CVEs in AF population.  
 
Study limitations 
The results are limited by: 1) retrospective analysis of an observational cohort, 2) relatively small ischemic 
cerebrovascular events.  Furthermore, analysis of CP was not centralized and, therefore, diagnosis was 
performed by each single center. However, the analysis should not be biased as each operator followed the AHA 
definition of CP and data were collected immediately after patient’s inclusion. Around 70% of patients in our 
cohort were taking oral anticoagulant therapy; nevertheless, we had not information on the quality of oral 
anticoagulation for all participants.  
Furthermore, most of our findings are based on NRI, which has limitations. In a simulation study, Pepe et al. 
[17] showed that with large data sets one might obtain a positive NRI even for a clinically irrelevant biomarker, 
for instance. We speculate that this situation might not apply in our study, as our sample size is much lower than 
the one used in Pepe's simulations. Additionally, in the simulations by Pepe et al. [17] a negative difference in 
C-index was always obtained, while in our study we observed a small but positive increase. It is well known that 
putatively relevant biomarkers might lead to tiny and non-significant increases in C-indexes; thus, we consider 
















In non-valvular AF patients the addition of CP to conventional VD increases the predictive value of CHA2DS2-
VASc score for stroke. Hence, analysis of CP could be included in the routine assessment of CHA2DS2-VASc 















Conflicts of interest-The authors declare that they have no conflict of interest. 
Dr. Hiatt reports grants from Bayer, Janssen and AstraZeneca, outside the submitted work. 
 
Author contributions:  
Basili S.- conception and  design of the study, acquisition and interpretation of data. 
Loffredo L. - interpretation of data. 
Pastori D. - acquisition of data. 
Proietti M. – acquisition of data. 
Farcomeni A. - analysis of data. 
Vestri A.R.- design of the study, analysis of data. 
Pignatelli P. - acquisition of data. 
Davì G.-   critical revision of data 
Hiatt W.R. – critical revision of the manuscript. 
Lip G.Y.H. – critical revision of the manuscript. 
Corazza G.R. – critical revision of the manuscript. 
Perticone F.– critical revision of the manuscript. 
Violi F.  - conception and design of the study; interpretation of data; drafting the article. 
















1) Kirchhof P, Breithardt G, Bax J, et al. A roadmap to improve the quality of atrial fibrillation management: 
proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus 
conference. Europace. 2016; 18: 37-50. 
2) Lip GY, Lane DA. Stroke prevention in atrial fibrillation: a systematic review. JAMA 2015; 313: 1950-62. 
3) Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants 
with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-62. 
4) Violi F, Daví G, Hiatt W,et al. Prevalence of peripheral artery disease by abnormal ankle-brachial index in 
atrial fibrillation: implications for risk and therapy. J Am Coll Cardiol 2013; 62: 2255-6.  
5) Pastori D, Pignatelli P, Angelico F, et al. Incidence of myocardial infarction and vascular death in elderly 
patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors. Chest. 2015; 147: 
1644-50.  
6) Violi F, Loffredo L. Thromboembolism or atherothromboembolism in atrial fibrillation? Circ Arrhythm 
Electrophysiol. 2012; 5: 1053-5. 
7) Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and 
thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial 
fibrillation. Chest 2010; 137: 263-72. 
8) Violi F, Davì G, Proietti M, et al. Ankle-Brachial Index and Cardiovascular Events in Atrial Fibrillation: 
ARAPACIS Prospective study. Thromb Haemost. 2016; 115: 856-63.  
9) Raparelli V, Proietti M, Buttà C, et al. Medication prescription and adherence disparities in non valvular atrial 
fibrillation patients: an Italian portrait from the ARAPACIS study. Intern Emerg Med 2014; 9: 861-70. 
10) Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound to identify subclinical vascular disease and 
evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography 
Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine J Am Soc 
Echocardiogr 2008; 21: 93-111. 
11) Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations 
to measure usefulness of new biomarkers. Stat Med. 2011; 30: 11-21. 
12) Vickers AJ, Cronin AM, Elkin EB, et al. Extensions to decision curve analysis, a novel method for 















13) Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic 
marker. Biometrics 2000; 56: 337-44. 
14) Proietti M, Calvieri C, Malatino L, et al. Relationship between carotid intima-media thickness and non 
valvular atrial fibrillation type. Atherosclerosis 2015; 238: 350-5.  
15) Bekwelem W, Jensen PN, Norby FL, Soliman EZ, Agarwal SK, Lip GY, Pan W, Folsom AR, Longstreth 
WT Jr, Alonso A, Heckbert SR, Chen LY. Carotid Atherosclerosis and Stroke in Atrial Fibrillation: The 
Atherosclerosis Risk in Communities Study. Stroke. 2016; 47:1643-6. 
16) Violi F, Calvieri C, Ferro D, et al. Statins as antithrombotic drugs. Circulation. 2013; 127: 251-7.  
17) Pepe MS, Fan J, Feng Z, Gerds T, Hilden J. The Net Reclassification Index (NRI): a Misleading Measure of 
















Figure 1: Proportions of patients with conventional vascular disease (VD) and VD+ ultrasound detection of 
carotid plaque (CP) according to Cerebrovascular Events (CVEs) occurrence. 
 
Figure 2: Event-Free Survival for Stroke/TIA Occurrence According to conventional vascular disease (VD) + 
ultrasound detection of carotid plaque (CP). 
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Table 1: Baseline Clinical Characteristics According to Cerebrovascular Events (CVEs) 
Occurrence 





Age, years (median [IQR b]) 74.4 [67.7-80.2] 80.1 [72.5-84.6] <0.001 
Female Gender, n (%) 885 (44.9) 33 (57.9) 0.052 
BMIa, kg/m2 (median [IQR])  27.2 [24.5-30.5] 26.8 [23.9-30.5] 0.473 
Atrial Fibrillation Type 
Paroxysmal, n (%) 
Persistent, n (%) 










Hypertension, n (%) 1,627 (82.6) 46 (80.7) 0.711 
Hypercholesterolemia, n (%) 754 (38.3) 27 (47.4) 0.164 
Smoking Habit, n (%) 295 (15.0) 9 (15.8) 0.865 
Diabetes, n (%) 454 (23.0) 12 (21.1) 0.724 
Heart Failure, n (%) 398 (20.2) 14 (24.6) 0.420 
Previous Stroke/TIA c, n (%) 220 (11.2) 15 (26.3) <0.001 
CHA2DS2-VASc (median [IQR]) 3 [2-4] 4 [3-5] <0.001 
CHA2DS2-VASc Classes 
Class 0, n (%) 
Class 1, n (%) 











None, n (%) 
Antiplatelets, n (%) 
VKA d, n (%) 












Statins, n (%) 718 (36.4) 18 (31.6) 0.451 
ACEe Inhibitors, n (%) 698 (35.4) 17 (29.8) 0.382 
ARBs f, n (%) 671 (34.1) 20 (35.1) 0.872 
Beta-Blockers, n (%) 799 (40.6) 23 (40.4) 0.975 















a Body Mass Index; bInterQuartile Range; cTransient Ischemic Attack;  dVitamin K Antagonist;  
















Table 2: Cox Regression Analysisa for Cerebrovascular Events [Stroke/ Transient Ischemic 
Attack (TIA)]. 
 HRb 95% CIc P 
Previous Stroke/TIA 2.41 1-31-4.44 0.0047 
Age (per year) 1.07 1.03-1.10 0.0001 
Conventional VDd 0.97 0.48-1.94 0.9288 
Previous Stroke/TIA 2.42 1.32-4.46 0.0044 
Age (per year) 1.07 1.03-1.10 0.0003 
VD+CPe 1.78 1.05-3.01 0.0318 
a
 level of entry into the model was set at a p-value = 0.10; badjusted hazard ratio;  
cconfidence interval; dconventional vascular disease (Myocardial infarction, aortic plaque, 

















Table 3: Reclassification Analysis for Cerebrovascular Events (CVEs) occurrence 
 NRIa 95% CIb p IDIc 95% CIb p 







VDd+CPe vs. VDd at 24 
months 
0.193 0.010-0.353 0.0399 0.003 -0.001-
0.010 
0.1262 
VDd+CPe vs. VDd at 36 
months 




aNet Reclassification Improvement; bConfidence Interval; cIntegrated Discrimination 
Improvement; dConventional Vascular Diseases (Myocardial infarction, aortic plaque, 
















Table 4: C-index for Cerebrovascular Events (CVEs) occurrence. 






















 at 24 months 0.609 0.561-0.663 <0.001 
VD
b





 at 36 months 0.626 0.586-0.666 <0.001 
VDb at 36 months 0.591 0.555-0.627 <0.001 
aConfidence Interval; bConventional Vascular Diseases (Myocardial infarction, aortic plaque, 
symptomatic peripheral artery disease); c ultrasound detection of carotid plaque. 
